A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study

What is this summary about?This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were treated with encorafenib plus cetuximab, with or without binimetinib, in the BEACON study. What were the results?Encorafenib plus cetuximab, with or without binimetinib, reduced the risk of participants dying compared with cetuximab plus chemotherapy, regardless of genetic or molecular colorectal cancer subtypes.The study also found genetic and molecular changes in the participants’ tumors during treatment that were associated with how long they lived. What do the results of the study mean?The types of genetic and molecular changes that occur during treatment in participants’ tumors can affect their response to treatment with BRAF and MEK inhibitors.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-05-09
DOI
https://doi.org/10.1080/14796694.2025.2498880
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study

Jie Pu, Hedieh Saffari, Josep M. Tabernero, Rona Yaeger et al.
Future Oncology
Colorectal Cancer Treatments and Studies
article

A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study

Jie Pu, Hedieh Saffari, Josep M. Tabernero, Rona Yaeger, Fortunato Ciardiello, Scott Kopetz, Phineas T. Hamilton, Takayuki Yoshino, Harpreet Wasan, Tao Xie, Jayesh Desai, Eric Van Cutsem, Xiaosong Zhang, Danielle Murphy
article en

Abstract

What is this summary about?This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were treated with encorafenib plus cetuximab, with or without binimetinib, in the BEACON study. What were the results?Encorafenib plus cetuximab, with or without binimetinib, reduced the risk of participants dying compared with cetuximab plus chemotherapy, regardless of genetic or molecular colorectal cancer subtypes.The study also found genetic and molecular changes in the participants’ tumors during treatment that were associated with how long they lived. What do the results of the study mean?The types of genetic and molecular changes that occur during treatment in participants’ tumors can affect their response to treatment with BRAF and MEK inhibitors.

Future OncologyVol. 21(14)
Universitat de Vic - Universitat Central de Catalunya (ES), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Pfizer (United States) (US), University of Campania "Luigi Vanvitelli" (IT), Universitair Ziekenhuis Leuven (BE), Peter MacCallum Cancer Centre (AU), Hammersmith Hospital (GB), Kettering University (US), Vall d'Hebron Hospital Universitari (ES), National Cancer Center Hospital East (JP), Imperial College London (GB), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 85%
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.